Signal transduction blockade and cancer: Combination therapy or multi-targeted inhibitors?

Annals of Oncology

Volumn 15, Issue 12, 2004, Pages 1727-1729

  Kerr, David J ^a   La Thangue, N B ^b  

^a RADCLIFFE INFIRMARY   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); BCR ABL PROTEIN; CISPLATIN; CYTARABINE; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FLAVANOID; FLUOROURACIL; GEFITINIB; HYBRID PROTEIN; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NEW DRUG; PACLITAXEL; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; PLATINUM DERIVATIVE; PRODRUG; PROTEIN KINASE C; PROTEIN P53; PROTEIN TYROSINE KINASE; QC 12; QUERCETIN; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BLAST CELL CRISIS; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 9; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG POTENTIATION; DRUG TARGETING; EDITORIAL; ENZYME ACTIVITY; EXPERIMENTAL DESIGN; GENE MUTATION; GENETIC CODE; HUMAN; HUMAN GENOME; MAXIMUM TOLERATED DOSE; MONOTHERAPY; NEPHROTOXICITY; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; SOLID TUMOR;

EID: 10944224663     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh480     Document Type: Editorial

References (6)

1. Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov 2002; 1: 727-730.
2. McLaughlin F, Finn P, La Thangue N. The cell cycle, chromatin and cancer: mechanism-based therapeutics come of age. Drug Discov Today 2003; 8: 793-802.
3. Druker BJ, David A. Karnofsky Award Lecture. Imatinib as a paradigm of targeted therapies. J Clin Oncol 2003; 21 (23 Suppl): 239s-245s.
4. Dancy JF, Freidlin B. Targeting epidermal growth factor receptor - are we missing the mark? Lancet 2003; 362: 62-64.
5. Ferry DR, Smith A, Malkhandi J et al. Phase I trial of the flavonoid quercetin: pharmacodynamics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res 1996; 2: 659-668.
6. Mulholland P, Ferry DR, Anderson et al. Pre-clinical and clinical study of QC12, a water-soluble, prodrug of quercetin. Ann Oncol 2001; 12: 245-248.